Introduction
Bronchodilators are the cornerstone of maintenance therapy for COPD, 1 one of the leading causes of mortality and morbidity worldwide. 2 Combined treatment with a long-acting muscarinic antagonist (LAMA) and a long-acting β 2 -agonist (LABA) plays an important role in the stepwise management of COPD. 3 The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends combined LAMA/ LABA treatment as a first-line therapy for patients with COPD in GOLD group D; and as a step-up treatment for patients in GOLD group C who experience frequent exacerbations despite LAMA or LABA monotherapy, and patients in GOLD group B 1 Glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) 18/9.6 µg (Bevespi Aerosphere ® ; AstraZeneca, Wilmington, DE, USA) is a fixed-dose combination (FDC) of the LAMA glycopyrrolate (GP) and the LABA formoterol fumarate (FF), formulated using innovative co-suspension delivery technology. GFF MDI is approved in the USA for the long-term maintenance treatment of airflow obstruction in patients with COPD 4 and, to date, is the first and only LAMA/LABA FDC available as an MDI.
The efficacy and safety of GFF MDI compared with respective monocomponents have been demonstrated over a period of up to 52 weeks in the pivotal Phase III studies PINNACLE-1, PINNACLE-2 (24 weeks; NCT01854645 and NCT01854658), and PINNACLE-3 (28-week safety extension study; NCT01970878), in patients from the USA, Australia, and New Zealand. 5, 6 Due to differences in COPD prevalence and burden between different countries and regions, [7] [8] [9] [10] as well as potential differences in the observed effects of pharmacological therapies, 11 it was deemed important to evaluate the efficacy and safety of COPD maintenance treatments in other geographical patient populations. Here, we present the results of the PINNACLE-4 study (ClinicalTrials.gov: NCT02343458), which investigated the efficacy and safety of GFF MDI compared to its monocomponents (GP MDI and FF MDI) and placebo MDI in a population with moderate-to-very severe COPD, which included Asian and European patients.
Methods study design and treatment
PINNACLE-4 was a randomized, double-blind, parallelgroup, placebo-controlled Phase III study conducted at multiple sites across Asia, Europe, and the USA. Patients were randomized 7:6:6:3 using an Interactive Web Response System (further details in the Supplementary materials) to receive treatment with GFF MDI 18/9.6 µg (equivalent to glycopyrronium/formoterol fumarate dihydrate 14.4/10 µg), GP MDI 18 µg, FF MDI 9.6 µg, or matched placebo MDI (all twice daily) for 24 weeks, with randomization stratified by reversibility to rescue albuterol sulfate and by COPD disease severity. Patients provided written informed consent prior to screening, and the study was conducted in accordance with Good Clinical Practice, including the Declaration of Helsinki and the International Council for Harmonisation. The protocol was approved by local institutional review boards (Table S1 ). Patients were required to discontinue prohibited COPD medications (including oral β 2 -agonists, LABAs, cromoglycate or nedocromil inhalers, leukotriene antagonists, ketotifen [except as eye drops], and LAMAs) following screening and were switched to sponsor-provided ipratropium bromide (administered four times daily) and albuterol sulfate (as needed) to control symptoms during the screening period. Patients using a maintenance FDC of an inhaled corticosteroid (ICS) and a LABA discontinued this, and were switched to the corresponding ICS monotherapy (fluticasone, mometasone, or budesonide) at an equivalent dose, as well as ipratropium bromide and albuterol sulfate (providing they had been maintained on a stable dose of the ICS component for $4 weeks prior to screening). Any patients taking a maintenance dose of an ICS not administered as an FDC with a LABA were allowed to continue using the ICS if they had been on a stable dose for $4 weeks prior to screening. Ipratropium bromide was discontinued after screening. Sponsor-provided albuterol sulfate was permitted, as needed, for the relief of symptoms throughout the study.
study population
Patients were 40-80 years of age and had an established clinical history of COPD as defined by the American Thoracic Society/European Respiratory Society. 12 Inclusion and exclusion criteria were the same as reported for PINNACLE-1 and PINNACLE-2. 5 Briefly, eligible patients were current or former smokers ($10 pack-years) with an FEV 1 /forced vital capacity ratio of ,0.70 and an FEV 1 of ,80% predicted normal value at screening. Further details are provided in the Supplementary materials. Patients were required to demonstrate stable baseline FEV 1 , ie, mean predose FEV 1 at randomization within ±20% or 200 mL of the mean of the predose FEV 1 assessment obtained at the previous two screening visits. The ability of patients to use the MDI correctly was confirmed at screening, with additional training provided as necessary.
assessments
The primary objective of the study was to compare the efficacy of GFF MDI with its monocomponents (GP MDI and FF MDI) and placebo MDI and also GP MDI and FF MDI with placebo MDI, in patients with moderate-to-very severe COPD. Study endpoints differed according to the regional regulatory registration requirements. This manuscript reports the approach that satisfies the filing requirements of the US and China regulatory authorities. Data for similar approaches and endpoints satisfying the filing requirements of other regions were also generated. The change from baseline in 
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gFF MDI in patients with COPD from asia, europe, and the Usa morning predose trough FEV 1 at Week 24 was the primary endpoint. Secondary lung function endpoints included change from baseline in morning predose trough FEV 1 over 24 weeks, peak change from baseline in FEV 1 within 2 hours postdosing at Week 24, and time to onset of action on Day 1 (defined as the first time point at which the difference from placebo MDI was statistically significant).
Other secondary endpoints included Transition Dyspnea Index (TDI) focal score over 24 weeks, change from baseline in St George's Respiratory Questionnaire (SGRQ) total score at Week 24 (intent-to-treat [ITT] population and symptomatic population), and change from baseline in mean daily rescue medication use over 24 weeks (rescue medication user population). Assessments of TDI focal score at Week 24 and SGRQ score over Weeks 12-24 were additional endpoints. Baseline Dyspnea Index (BDI) and TDI were assessed using the interviewer-administrated version of the BDI/TDI questionnaire. 13, 14 Other efficacy endpoints included responder analyses to determine the proportion of patients achieving an improvement of the minimal clinically important difference (MCID) threshold of $1 unit in TDI focal score 15 over 24 weeks and $4 units in SGRQ score 16 at Week 24. Safety assessments included electrocardiograms (ECGs), clinical laboratory testing, and vital sign measurements. Adverse events (AEs) were monitored throughout the study.
statistical analysis
Unless otherwise specified, results were based on analyses using the ITT population (all patients who were randomized and received any study treatment, even if ,1 full dose). The safety population was the same as the ITT population, except patients who were analyzed according to treatment received rather than treatment assigned. The symptomatic population included all patients in the ITT population with a COPD assessment test (CAT) score of $15 at screening. The rescue medication user population included all patients in the ITT population with the mean baseline rescue medication use (albuterol sulfate) of $1 puff/day (calculated from the last 7 days of the 10-14 days screening period).
A sample size of 1,614 patients was estimated to provide 91% of power to detect differences for all primary comparisons (GFF MDI vs placebo MDI and each monocomponent and each monocomponent vs placebo MDI) in the primary endpoint (change from baseline in morning predose trough FEV 1 at Week 24) with Type I error controlled at a twosided α level of 0.05. The same sample size was estimated to provide 99% of power to detect differences for the same comparisons for change from baseline in morning predose trough FEV 1 over 24 weeks.
The primary and secondary endpoints (with the exception of time to onset of action) were analyzed using repeated measures linear models (further details in the Supplementary materials). Strong control of Type I error (two-sided α=0.05) was implemented sequentially across the five key comparisons for the primary endpoint and then simultaneously across the secondary endpoints within a key comparison using the Hochberg procedure (two-sided α=0.05).
Results

Patient disposition
A total of 1,756 patients were randomized and received treatment (714 patients from Asia, 496 patients from the USA, and 546 patients from Europe [including Russia]), and 1,528 (87%) patients completed the study (Figure 1 ). The ITT and safety populations included 1,740 patients, of whom 841 patients were symptomatic (baseline CAT score $15). The rescue medication user population comprised 822 patients. Patient demographics and baseline characteristics are summarized in Table 1 . The mean age of the patient was 64.2 years, 74.1% of them were male, and 40.2% of them were Asian (56.7% White).
Efficacy
For the primary endpoint of change from baseline in morning predose trough FEV 1 at Week 24, treatment with GFF MDI resulted in significantly greater improvements vs placebo MDI (least squares mean [LSM] difference: 165 mL; P,0.0001; Figure 2 and Table 2 ), GP MDI (LSM difference: 59 mL; P,0.0001), and FF MDI (LSM difference: 72 mL; P,0.0001). GP MDI and FF MDI treatments significantly increased morning predose trough FEV 1 at Week 24 compared to placebo MDI (LSM difference 105 and 92 mL, respectively; both P,0.0001; Figure 2 ). Similar improvements as for the primary endpoint were observed for change from baseline in morning predose trough FEV 1 over 24 weeks ( Figure 2 and Table 2 ). GFF MDI led to significant improvements in peak change from baseline in FEV 1 within 2 hours postdose at Week 24 compared to GP MDI, FF MDI, and placebo MDI ( both the ITT population and the symptomatic population following treatment with GFF MDI compared with GP MDI and placebo MDI (P,0.05) but not with FF MDI (Table 3) . Improvements in TDI score at Week 24 and SGRQ score over Weeks 12-24 were also greater following GFF MDI treatment compared to GP MDI and placebo MDI in both populations (Table S2 ). Patients treated with GFF MDI were more likely to achieve an improvement in at least the MCID for TDI score ($1.0 unit) and SGRQ score ($4.0 unit decrease) vs placebo MDI and versus GP MDI for TDI score (ITT population and symptomatic population; Table 4 ). Significant improvements in rescue medication use were observed for GFF MDI vs GP MDI (LSM difference: -0.77; P=0.0001) and placebo MDI in the rescue medication user population (LSM difference: -0.98; P,0.0001; Table 3 ).
safety
The incidence of treatment-emergent AEs (TEAEs), treatment-related TEAEs, serious TEAEs, or TEAEs leading to discontinuation was similar across treatment groups (Table 5) , with the majority of TEAEs being mild or moderate and not considered related to study treatment. A relatively low proportion of patients (ranging from 4.3% with placebo MDI to 5.3% with GP MDI) discontinued due to TEAEs.
The most commonly reported TEAEs included upper respiratory tract infection, worsening of COPD, headache, and hypertension (Table 5) .
One death occurred in each of the treatment groups (lung cancer [metastatic; n=1 with both GFF MDI and placebo MDI], hemorrhagic stroke [GP MDI], and hypoglycemic coma [FF MDI]). None of these deaths were judged by the investigator to be related to study drug treatment.
Discussion
Treatment with the LAMA/LABA FDC, GFF MDI, improved lung function compared to placebo MDI and monocomponents and improved symptoms and patient-reported outcomes compared to placebo MDI and GP MDI in a population of patients with moderate-to-very severe COPD from Asia, Europe, and the USA. Improvements in the primary endpoint -change from baseline in morning predose trough FEV 1 at Week 24 -exceeded the MCID of 100 mL 17 for both GFF MDI and GP MDI vs placebo MDI and were significantly higher following treatment with GFF MDI vs monocomponents. Overall, results confirmed those from previous Phase III studies, which showed GFF MDI to be efficacious and well tolerated in a population that included patients from the USA, Australia, and New Zealand. 5, 6 International Journal of COPD 2018:13 submit your manuscript | www.dovepress.com
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gFF MDI in patients with COPD from asia, europe, and the Usa Improvements in the secondary lung function endpoint (peak change from baseline in FEV 1 within 2 hours postdose at Week 24) as well as rescue medication use were significantly larger in the GFF MDI treatment arm vs monocomponents and placebo MDI and similar to those observed in PINNACLE-1 and PINNACLE-2.
5,18 TDI focal scores indicated greater reductions in breathlessness following GFF MDI treatment than comparators, although treatment differences were only significant compared with GP MDI and placebo MDI (ITT and symptomatic populations). The treatment difference for GFF MDI vs placebo MDI in TDI score over 24 weeks was larger than that observed in PINNACLE-1 and PINNACLE-2, which may be in part due to differences in the method of assessment of TDI score (the interviewer-administered version of the TDI was used in this study vs the self-administered, computerized version used in PINNACLE-1 and PINNACLE-2). 19 A larger proportion of patients in the GFF MDI group achieved a clinically relevant improvement in TDI (total score $1 unit) 15 vs GP MDI and placebo MDI in the symptomatic and ITT populations, demonstrating that GFF MDI was effective in reducing breathlessness in patients with COPD. The results of the SGRQ assessment in this study suggest that GFF MDI may improve health-related quality of life (HRQoL) compared c These patients were characterized as having mild COPD due to the application of an asian correction factor to baseline lung function assessments at the time of analysis. Reversible is defined as improvement in FEV 1 postalbuterol administration compared to the prealbuterol of $12% or $200 ml.
e Defined as using ICS on the day of the first dose of study medication.
f CaT total score is the sum of eight CaT item scores (range: 0-40). with placebo MDI and GP MDI, which is consistent with the results of PINNACLE-1. 5, 18 Although the improvements seen with GFF MDI in patient-reported outcomes (TDI and SGRQ) were not statistically significant vs FF MDI, both treatments were effective in improving symptoms vs placebo. Differences between active treatments for patientreported outcomes can be small and, therefore, these outcome measures may not be sensitive in indicating differences 
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gFF MDI in patients with COPD from asia, europe, and the Usa between active treatments. Ultimately, the superior effects of GFF MDI vs FF MDI on lung function may result in greater benefits for patients' quality of life when sustained over a longer time period than the 24-week duration of the current study. In the long-term PINNACLE-3 safety study, treatment with GFF MDI resulted in statistically significant improvements in TDI score and numerical improvements in SGRQ, over 52 weeks compared with FF MDI. 6 Although no head-to-head comparisons between GFF MDI and other LAMA/LABA FDCs have been reported, the magnitude of improvements in lung function, rescue medication use, and HRQoL vs monocomponents observed in this study followed a similar trend to those of pivotal studies with other LAMA/LABA FDCs. [20] [21] [22] [23] [24] [25] [26] [27] While several other efficacious and well-tolerated LAMA/LABA FDC combinations are available for the maintenance treatment of COPD, GFF MDI is notably the first to be delivered using an MDI. The co-suspension delivery technology used to formulate GFF MDI overcame formulation challenges encountered with MDIs, 28 resulting in consistent in vitro aerosol performance, even in the presence of simulated patient-handling errors, 29 providing reliable drug dose delivery to all regions of the lungs with high efficiency. 30 As familiarity with an inhaler can result in more favorable clinical outcomes in respiratory disease 31, 32 and MDIs remain a commonly prescribed device type for rescue medication, 33 the availability 
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gFF MDI in patients with COPD from asia, europe, and the Usa of a LAMA/LABA FDC delivered by MDI offers a useful option for the maintenance treatment of COPD. A Phase III study has shown that the addition of a spacer does not affect the lung function benefits and tolerability of GFF MDI, 35 suggesting that this FDC could be a treatment option for patients who require a spacer to compensate for poor hand-to-breath coordination with an MDI.
A potential limitation of this study was the short duration (6 months) relative to expected use as prophylactic therapy. However, the long-term safety and efficacy of GFF MDI have been evaluated over a 1-year period during the PINNACLE-3 safety extension study. 6 Additionally, patients could have potentially perceived benefit from participation in a study of the novel co-suspension delivery technology MDI. However, placebo was delivered by the same device as the active treatments to control for effects due to patient perception. The strength of this study was that patients were enrolled from sites across Asia, Europe, and the USA, allowing the efficacy and safety of GFF MDI to be evaluated in patients from a broad range of geographical locations and socioeconomic backgrounds. Patients were not required to be symptomatic at baseline for enrollment, though results were analyzed in a subgroup of patients with a CAT score of $15 (48% of patients randomized), which provided an insight into the efficacy of GFF MDI in symptomatic patients.
Conclusion
The results of PINNACLE-4 demonstrate that GFF MDI improves lung function, symptoms, and patient-reported outcomes in a study population including patients from Asia, Europe, and the USA. These results are consistent with previous Phase III studies with GFF MDI, which showed that this LAMA/LABA FDC was efficacious and well tolerated with no unexpected safety signals in patients with moderateto-very severe COPD.
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statistical analysis
The primary endpoint was analyzed using a repeated measures linear model with baseline FEV 1 (the mean of evaluable 60-and 30-minute predose values on Day 1) and reversibility to albuterol sulfate as continuous covariates and visit, treatment, and treatment-by-visit interaction as categorical covariates. An unstructured variance-covariance matrix was applied, and two-sided P-values and point estimates with two-sided 95% CIs were produced for each treatment difference. Treatment group comparisons for the secondary endpoints were evaluated using a similar repeated measures linear model as for the primary endpoint but included the relevant baseline covariate for each endpoint. Time to onset of action on Day 1 was determined for each treatment using the 5 and 15-minute postdosing FEV 1 assessments and analyzed using an analysis of covariance model, with baseline FEV 1 and reversibility to albuterol sulfate as continuous covariates. For Transition Dyspnea Index and St George's Respiratory Questionnaire responder analyses, logistic regression was used to compare treatment groups and P-values and odds ratios with 95% CIs were produced for each comparison. The procedure to control Type I error was applied to primary and secondary endpoints only and is described in the main body of the article. a Approval numbers are shown where available (some IRBs provided reference or file numbers and some did not assign approval numbers). Abbreviations: IrBs, institutional review boards; na, not available; reC, research ethic Committee; Iras, Integrated research approval system; TCVgh, Taichung Veterans general hospital; nTUh-rec, national Taiwan University hospital research ethic Committee; CFDa, China Food and Drug administration; eC, ethics committee; sFDa, state Food and Drug administration.
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